|Back to main|
Kite Pharma prices IPO at $17, above the range
By: Renaissance Capital
Kite Pharma, a biotech developing cancer immunotherapies with the National Cancer Institute, raised $128 million by offering 7.5 million shares at $17, above the upwardly revised range of $15 to $16. Kite Pharma plans to list on the NASDAQ under the symbol KITE. Kite Pharma initially filed confidentially on 4/4/2014. Jefferies & Co., Credit Suisse and Cowen & Company acted as lead managers on the deal.